Research Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Zacks Research dropped their Q1 2026 earnings per share estimates for Biogen in a research report issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $3.49 per share for the quarter, down from their prior forecast of $3.59. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

A number of other research firms have also recently commented on BIIB. Scotiabank reduced their price objective on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 13th. Citigroup reduced their price objective on Biogen from $160.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Mizuho reduced their price objective on Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Bank Of America (Bofa) reduced their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a research report on Tuesday, February 11th. Finally, The Goldman Sachs Group reduced their price objective on Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Biogen currently has an average rating of “Hold” and an average target price of $213.33.

Biogen Trading Down 0.4 %

Shares of NASDAQ:BIIB opened at $139.44 on Friday. The company has a market cap of $20.41 billion, a P/E ratio of 12.46, a PEG ratio of 1.51 and a beta of 0.01. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00. The stock’s fifty day moving average price is $143.09 and its 200-day moving average price is $164.30.

Insider Activity at Biogen

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This trade represents a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Several institutional investors have recently modified their holdings of BIIB. Larson Financial Group LLC lifted its stake in shares of Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 141 shares during the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen in the fourth quarter worth approximately $25,000. Colonial Trust Co SC raised its holdings in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after buying an additional 186 shares during the period. OFI Invest Asset Management purchased a new stake in shares of Biogen in the fourth quarter worth approximately $32,000. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of Biogen in the third quarter worth approximately $33,000. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.